MAPT and Alzheimer disease: This study is supported by preclinical data demonstrating the high binding affinity of gosuranemab to monomeric and aggregated forms of tau and its ability to remove seeding-competent forms of tau from AD brain lysate and interstitial fluid derived from tau transgenic mice18.